Investigation of Administration of MCT/ω-3 Fatty Acids is Towards Anti-inflammatory Related Fatty Acid Profile in Preterm Neonates.
- Conditions
- Premature Birth
- Interventions
- Dietary Supplement: soybean oil-based IVFEDietary Supplement: MCT/ω-3 fatty acids
- Registration Number
- NCT04586608
- Lead Sponsor
- Iaso Maternity Hospital, Athens, Greece
- Brief Summary
Intravenous administration of pure soybean oil emulsions high in linoleic acid may lead to inflammation and lipid peroxidation in preterm neonates. The aim of the present study was to investigate the effects of a medium-chain triglyceride (MCT)/n-3 polyunsaturated fatty acid (PUFA)-enriched intravenous fat emulsion (IVFE) on plasma fatty acid (FA) profile in preterm neonates. Methods: In this double-blind randomized study, 92 preterm neonates (gestational age \<32 weeks, birth weight \<1500g) were assigned to receive either MCT/n-3 PUFA-enriched IVFE (Intervention Group) or soybean oil-based IVFE (Control Group). Neonates' parents gave their informed written consent for inclusion in the study. Levels of FAs were measured at baseline (day 0) and day 15 of parenteral nutrition with gas-chromatography mass-spectrometry.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 92
Preterm neonates with gestational age <32 weeks
- birth weight <1500 g
- admitted to a tertiary neonatal intensive care unit within 12 hours after birth
- anticipated needs for parenteral nutrition (PN) at ˃70% of total daily energy for <10 days evidence of intrauterine infection,
- perinatal asphyxia
- major congenital anomalies
- refusal of parental consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description soybean oil-based IVFE soybean oil-based IVFE soybean oil-based IVFE active comparator MCT/ω-3 fatty acids -
- Primary Outcome Measures
Name Time Method Alterations on Metabolic Fatty Acid Profile of the Premature Neonates two years the detection of clinically significant differences in plasma n-3 PUFAs, n-6 PUFAs and EPA in the MCT/ω-3 PUFA-enriched IVFE group compared to the SO-IVFE group post intervention.
the detection of clinically significant differences in plasma n-3 PUFAs, n-6 PUFAs and EPA in the MCT/ω-3 PUFA-enriched IVFE group compared to the SO-IVFE group post intervention.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Panos Papandreou
🇬🇷Athens, Greece